A Practical Approach to the Diagnosis and Treatment of Anemia in Cancer Patients
The decision regarding the best treatment option for cancer patients with anemia is dependent on many factors including the presence of symptoms, etiology of anemia, chemotherapy treatment intent and patient comorbidities. While red blood cell (RBC) transfusion is best for symptomatic patients requiring an immediate boost in hemoglobin levels, consideration of erythropoiesis-stimulating agent (ESA) therapy and/or iron supplementation may be warranted for the long-term management of anemia in high-risk patients or in asymptomatic patients with comorbidities.
NCCN 2020 Nursing Program: A Practical Approach to the Diagnosis and Treatment of Anemia in Cancer Patients
The decision regarding the best treatment option for cancer patients with anemia is dependent on many factors including the presence of symptoms, etiology of anemia, chemotherapy treatment intent and patient comorbidities. While red blood cell (RBC) transfusion is best for symptomatic patients requiring an immediate boost in hemoglobin levels, consideration of erythropoiesis-stimulating agent (ESA) therapy and/or iron supplementation may be warranted for the long-term management of anemia in high-risk patients or in asymptomatic patients with comorbidities.
New Biosimilar Approvals for Myeloid Growth Factors and Anemia

Challenges remain in the acceptance of biosimilar medications by physicians, payers, and patients in the U.S., similar to the challenges faced by generic drugs when they were first introduced to the market.

Management of Anemia: ESAs Reconsidered

This information was originally presented on September 15, 2012, at the NCCN 7th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Subscribe to RSS - Anemia